August 16, 2019 / 2:51 PM / a year ago

Roche prices personalized cancer treatment at about $204,560 annually

Aug 16 (Reuters) - Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

The treatment was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumors, which show rare genetic anomalies called NTRK fusions.

The treatment also won approval to treat adults with non-small cell lung cancer, whose tumors show genetic mutations called ROS1 fusions. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below